<DOC>
	<DOCNO>NCT01240252</DOCNO>
	<brief_summary>The study conduct find much fat blood stream may cause insulin resistance muscle . Insulin hormone , produce normally body , cause blood sugar return normal eat .</brief_summary>
	<brief_title>Insulin Receptor Substrate 1 ( IRS-1 ) Regulation Insulin Resistance</brief_title>
	<detailed_description>Insulin resistance skeletal muscle early event pathogenesis type 2 diabetes , obesity , condition associate Metabolic Syndrome . The aim study determine extent inflammatory response lipid present naturally occur insulin resistance . We test hypothesis skeletal muscle insulin resistant volunteer characterize : 1 . Increased concentration circulate proinflammatory cytokine without change cytokine expression muscle . 2 . Increased inflammatory response muscle . 3 . Increased infiltration inflammatory cell skeletal muscle . 4 . Changes expression proteasome gene . Forty five subject study total . Three group study . One group consist 15 patient type 2 diabetes mellitus The second group consist 15 age , gender , body composition match overweight obese subject ( 27 &lt; BMI &lt; 36 ) normal glucose tolerance . The third group consist 15 age gender match nonobese control subject ( BMI &lt; 27 ) . There two visit study , screen visit study visit . At visit 2 subject report study site fast since night , discus study provide write consent , provide history physical exam . Screening test include 12-lead resting EKG , complete blood chemistry complete blood count ( CBC ) , glycated hemoglobin ( HbA1c ) , lipid profile . If result test show subject eligible participate study , second visit schedule . On day screen visit , patient oral glucose tolerance test . Within 3 month screen visit , subject return overnight fast euglycemic clamp study 2 muscle biopsy . Diabetic subject oral medication discontinue 3 day study ( metformin thiazolidinedione treatment exclude ) . Patients take insulin neutral protamine Hagedorn ( NPH ) discontinue even study , Glargine discontinue morning evening day study . An antecubital catheter place infusion substance . Deuterated glucose use determine rate basal insulin stimulate glucose uptake . A hand vein catheterize place heat box arterialize venous blood measurement arterial glucose concentration . One hour later , percutaneous biopsy vastus lateralis muscle perform . Biopsy specimens ( 75-150 mg ) freeze immediately liquid nitrogen store liquid nitrogen process . One hour muscle biopsy ( two hour start deuterated glucose ) , primed-continuous ( 80 milliunits ( mU ) / ( m^2 per min ) ) insulin infusion start continue 120 minute quantify effect insulin glucose disposal . Throughout insulin infusion , infusion 20 % glucose adjust maintain euglycemia . Plasma glucose diabetic allow fall insulin infusion euglycemia , maintain . A second muscle biopsy perform contralateral leg conclusion insulin infusion .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Age 3065 Healthy lean , obese , know type 2 diabetic Body Mass Index ( BMI ) less 36 All nondiabetic subject must normal oral glucose tolerance Subjects must follow laboratory value : 1 . Hematocrit ≥ 35 vol % 2 . Serum creatinine ≤ 1.6 mg/dl 3 . Aspartate aminotransferase ( AST ) ( SGOT ) &lt; 2 time upper limit normal 4 . Alanine aminotransferase ( ALT ) ( SGPT ) &lt; 2 time upper limit normal 5 . Alkaline phosphatase &lt; 2 time upper limit normal 6 . Triglycerides &lt; 150 mg/dl 7 . Prothrombin time ( PT ) 11.7 14.3 second 8 . Partial thromboplastin time 23.037.0 second Exclusion criterion : No disease know affect glucose metabolism healthy type 2 diabetes Subjects must receive follow medication : thiazide furosemide diuretic , betablockers , chronic medication know adverse effect glucose tolerance level unless patient stable dose agent past three month entry study . Subjects may take stable dose estrogens hormonal replacement therapy , subject agent prior three month . Subjects take systemic glucocorticoid exclude . Subjects history clinically significant heart disease ( New York Heart Classification great grade II ; nonspecific STT wave change EKG ) , peripheral vascular disease ( history claudication ) , pulmonary disease ( dyspnea exertion one flight le ; abnormal breath sound auscultation ) study . Recent systemic pulmonary embolus , untreated highrisk proliferative retinopathy , recent retinal hemorrhage , uncontrolled hypertension , systolic BP &gt; 180 , diastolic BP &gt; 105 , autonomic neuropathy , rest heart rate &gt; 100 , electrolyte abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin resistance</keyword>
</DOC>